[go: up one dir, main page]

EA202191301A1 - СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА - Google Patents

СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА

Info

Publication number
EA202191301A1
EA202191301A1 EA202191301A EA202191301A EA202191301A1 EA 202191301 A1 EA202191301 A1 EA 202191301A1 EA 202191301 A EA202191301 A EA 202191301A EA 202191301 A EA202191301 A EA 202191301A EA 202191301 A1 EA202191301 A1 EA 202191301A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazin
quinolin
imidazo
benzamide
ylmethyl
Prior art date
Application number
EA202191301A
Other languages
English (en)
Inventor
Элизабете Гонкалвеш
Кристин Таухманн
Шау-Фонг Йен
Судха Виппагунта
Чжисинь Цзун
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202191301(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA202191301A1 publication Critical patent/EA202191301A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к таблеткам, содержащим 2-фтор-N-метил-4-[7-(хинолин-6-илметил)имидазо[1,2-b][1,2,4]триазин-2-ил]бензамид, способу их изготовления и применению в лечении некоторых видов рака.
EA202191301A 2014-07-25 2015-07-22 СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА EA202191301A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25

Publications (1)

Publication Number Publication Date
EA202191301A1 true EA202191301A1 (ru) 2021-11-30

Family

ID=53762251

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202191301A EA202191301A1 (ru) 2014-07-25 2015-07-22 СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
EA201790259A EA039220B1 (ru) 2014-07-25 2015-07-22 СОСТАВ ТАБЛЕТКИ 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790259A EA039220B1 (ru) 2014-07-25 2015-07-22 СОСТАВ ТАБЛЕТКИ 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА

Country Status (30)

Country Link
US (4) US10085993B2 (ru)
EP (2) EP3172209B1 (ru)
JP (3) JP6770946B2 (ru)
KR (2) KR20230136693A (ru)
CN (2) CN106714784A (ru)
AR (1) AR101286A1 (ru)
AU (4) AU2015293539A1 (ru)
CA (1) CA2954840A1 (ru)
CL (1) CL2017000180A1 (ru)
CO (1) CO2017000586A2 (ru)
DK (1) DK3172209T3 (ru)
EA (2) EA202191301A1 (ru)
EC (1) ECSP17011672A (ru)
ES (1) ES2857523T3 (ru)
FR (1) FR22C1058I2 (ru)
GT (1) GT201700007A (ru)
HU (2) HUE053346T2 (ru)
IL (1) IL250166B (ru)
JO (1) JO3618B1 (ru)
MX (2) MX2017001177A (ru)
MY (1) MY187276A (ru)
NO (1) NO2022058I1 (ru)
PE (1) PE20170523A1 (ru)
PH (1) PH12017500121A1 (ru)
PL (1) PL3172209T3 (ru)
PT (1) PT3172209T (ru)
SG (2) SG11201700147SA (ru)
SI (1) SI3172209T1 (ru)
TW (2) TW202200148A (ru)
WO (1) WO2016012963A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
JP6875501B2 (ja) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2023324893A1 (en) * 2022-08-19 2025-03-13 Mirati Therapeutics, Inc. Adagrasib solid pharmaceutical compositions
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
JP2009502807A (ja) 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
DK1928409T3 (da) 2005-09-12 2012-11-05 Actelion Pharmaceuticals Ltd Stabil farmaceutisk sammensætning omfattende pyrimidin-sulfamid
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
RS52677B (en) 2006-11-22 2013-06-28 Incyte Corporation IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE
CN103936743B (zh) * 2008-05-21 2018-04-24 因西特控股公司 2-氟-N-甲基-4-[7-(喹啉-6-基甲基)咪唑并[1,2-b][1,2,4]三嗪-2-基]苯甲酰胺的盐及与其相关的制备方法
ES2757882T5 (es) * 2009-11-09 2023-05-10 Wyeth Llc Formulaciones de comprimidos de maleato de neratinib
SI3257500T1 (sl) 2010-02-25 2019-12-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
MY161078A (en) * 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
AU2011276332A1 (en) * 2010-07-06 2013-01-17 Janssen Pharmaceutica Nv Formulation for co-therapy treatment of diabetes
MX369518B (es) 2012-08-16 2019-11-11 Novartis Ag Combinacion de inhibidor de p13k e inhibidor de c-met.
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide

Also Published As

Publication number Publication date
AU2021202500A1 (en) 2021-05-20
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
JP7002587B2 (ja) 2022-01-20
TW201613595A (en) 2016-04-16
PT3172209T (pt) 2021-02-11
US20220249498A1 (en) 2022-08-11
AU2020200912A1 (en) 2020-02-27
CO2017000586A2 (es) 2017-06-20
GT201700007A (es) 2018-12-18
ECSP17011672A (es) 2018-03-31
JP2020114852A (ja) 2020-07-30
PE20170523A1 (es) 2017-05-17
US10596178B2 (en) 2020-03-24
EP3172209B1 (en) 2020-12-02
EA201790259A1 (ru) 2017-06-30
NZ728089A (en) 2024-01-26
MX2017001177A (es) 2017-05-01
KR20170039211A (ko) 2017-04-10
SG11201700147SA (en) 2017-02-27
WO2016012963A1 (en) 2016-01-28
PH12017500121A1 (en) 2017-05-29
CN115364061A (zh) 2022-11-22
MX2021000595A (es) 2021-04-13
FR22C1058I2 (fr) 2023-11-17
SI3172209T1 (sl) 2021-03-31
IL250166A0 (en) 2017-03-30
US20190015418A1 (en) 2019-01-17
NO2022058I1 (no) 2022-12-16
JP2017521469A (ja) 2017-08-03
BR112017000953A2 (pt) 2017-11-14
CA2954840A1 (en) 2016-01-28
KR102581121B1 (ko) 2023-09-21
US20210113569A1 (en) 2021-04-22
FR22C1058I1 (fr) 2023-01-06
IL250166B (en) 2021-01-31
MY187276A (en) 2021-09-17
AU2015293539A1 (en) 2017-02-02
US20170231997A1 (en) 2017-08-17
KR20230136693A (ko) 2023-09-26
JO3618B1 (ar) 2020-08-27
JP2022046659A (ja) 2022-03-23
HUE053346T2 (hu) 2021-06-28
EA039220B1 (ru) 2021-12-20
US12208101B2 (en) 2025-01-28
DK3172209T3 (da) 2021-02-22
US10085993B2 (en) 2018-10-02
JP6770946B2 (ja) 2020-10-21
PL3172209T3 (pl) 2021-06-14
HUS2200054I1 (hu) 2023-01-28
TW202200148A (zh) 2022-01-01
TWI724993B (zh) 2021-04-21
CL2017000180A1 (es) 2017-09-15
EP3172209A1 (en) 2017-05-31
ES2857523T3 (es) 2021-09-29
AR101286A1 (es) 2016-12-07
EP3848376A1 (en) 2021-07-14
SG10201900648SA (en) 2019-02-27
AU2018207947A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
EA201890204A1 (ru) Антибактериальные соединения
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
MX373845B (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio.
PH12019500535A1 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201691907A1 (ru) Комбинированная терапия кураксинами